Synbiobeta

Synbiobeta Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Synbiobeta, Biotechnology company, Pleasant Hill, CA.

Synthetic Biology Events & Industry Information
🌍 Global Synthetic Biology Conference
📅 May 4-7, 2026 in San Jose
Join us!

tinyurl.com/2uc677rn Built With Biology is the premier innovation network for biological engineers, innovators, entrepreneurs, and investors who share a passion for using biology to build a better, more sustainable planet. We provide our community members with

personal and professional development support, as well as valuable opportunities for networking, partnership, collaboration, and education. Every year we host The Global Synthetic Biology Summit which showcases the cutting-edge developments in biology that are transforming how we fuel, heal, and feed the world. In addition, we stage a variety of other conferences, thought leader retreats, and local meet-ups throughout the year, in both the United States and around the world.

Chorus Studios launches "Talk BIO to Me" mini-pod this week. The series features short interviews recorded at SynBioBeta...
06/10/2026

Chorus Studios launches "Talk BIO to Me" mini-pod this week. The series features short interviews recorded at SynBioBeta. Subscribe wherever you get your podcasts to hear the first two full-length episodes later this week.

https://talkbiotome.transistor.fm/

LanzaTech has selected North Sea Port Ghent as the site of Europe’s first commercial alcohol-to-jet sustainable aviation...
06/07/2026

LanzaTech has selected North Sea Port Ghent as the site of Europe’s first commercial alcohol-to-jet sustainable aviation fuel facility. The project aims to transform carbon-based feedstocks into lower-carbon aviation fuel.

https://www.globenewswire.com/news-release/2026/05/11/3291673/0/en/LanzaTech-Selects-North-Sea-Port-Ghent-as-Site-for-Europe-s-First-Commercial-Alcohol-to-Jet-SAF-Facility.html

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

ParcelBio has launched with $13 million in financing to advance next-generation mRNA medicines. The company aims to deve...
06/07/2026

ParcelBio has launched with $13 million in financing to advance next-generation mRNA medicines. The company aims to develop technologies that expand the potential of mRNA-based therapeutics.

https://www.businesswire.com/news/home/20260507530407/en/ParcelBio-Launches-with-%2413-Million-in-Financing-to-Advance-Next-Generation-mRNA-Medicines

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

Eli Lilly is acquiring Kelonia Therapeutics in a deal worth up to $7 billion, gaining access to the company's iGPS gene ...
06/07/2026

Eli Lilly is acquiring Kelonia Therapeutics in a deal worth up to $7 billion, gaining access to the company's iGPS gene placement platform for in vivo cell therapy.

https://news.google.com/rss/articles/CBMitgFBVV95cUxPSjdXVHo2Y1pMb2hZXzJ3ZnAzWFBsRENiaFdxWWpJdTNEYVdCd0RZUzBZZDFZTDJGajRISklIamJDTUI4Tnp0bmd0M1ZZeXpjalZPbmZrWEU3YnJTZU8xSy1GTklhcDZWYi1JcnAtbzFnNUlFeERPbWV0aVVWZ2I2d01zU055X0dxa1FYZV9BRV9mVHllMExiMGxTMVlxM043d1g1SEhZNy1NWVVIVEkwbmdOcUo3QQ

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

The intellectual property dispute involving Onego Bio has intensified as legal challenges continue to unfold around alte...
06/07/2026

The intellectual property dispute involving Onego Bio has intensified as legal challenges continue to unfold around alternative protein technologies and commercialization rights.

https://agfundernews.com/every-urges-court-to-sanction-onego-bio-as-alt-protein-ip-fight-turns-nasty

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

Praio launched its Environmental Screening Panel at SynBioBeta 2026, introducing a commercial platform designed to help ...
06/07/2026

Praio launched its Environmental Screening Panel at SynBioBeta 2026, introducing a commercial platform designed to help organizations identify and monitor environmental biological risks.

https://www.synbiobeta.com/read/praio-launches-environment-screening-panel-at-synbiobeta-2026

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

Benchling introduced three new products during SynBioBeta 2026, highlighting its continued investment in AI-enabled R&D ...
06/07/2026

Benchling introduced three new products during SynBioBeta 2026, highlighting its continued investment in AI-enabled R&D infrastructure and digital tools designed to support scientific innovation.

https://www.synbiobeta.com/read/benchling-launches-three-products-during-synbiobeta-2026-%E2%80%94-and-its-head-of-ai-hints-at-what-comes-next

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

UCB has agreed to acquire Candid Therapeutics in a transaction valued at up to $2.2 billion. The deal adds Candid’s T-ce...
06/07/2026

UCB has agreed to acquire Candid Therapeutics in a transaction valued at up to $2.2 billion. The deal adds Candid’s T-cell engager platform and lead candidate, cizutamig, to UCB’s growing immunology portfolio.

https://www.candidrx.com/ucb-to-acquire-candid-therapeutics-building-upon-its-existing-immunology-pipeline-with-novel-t-cell-engagers/

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

Odyssey Therapeutics raised $279 million through an upsized IPO, providing capital to advance its pipeline of treatments...
06/07/2026

Odyssey Therapeutics raised $279 million through an upsized IPO, providing capital to advance its pipeline of treatments for autoimmune and inflammatory diseases, including lead candidate OD-001.

https://www.reuters.com/business/healthcare-pharmaceuticals/biotech-firm-odyssey-raises-279-million-upsized-us-ipo-2026-05-08/

Want to stay ahead in biotech? Subscribe to our newsletter for more 🧬. https://www.syntheticbiologysummit.com/signup?utm_source=Facebook&utm_medium=newsletter&utm_campaign=newsletter_top5&utm_content=digest_644

Address

Pleasant Hill, CA

Website

,

Alerts

Be the first to know and let us send you an email when Synbiobeta posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Synbiobeta:

Shortcuts

Share

Category